这是一篇来自已证抗体库的有关人类 KRT75的综述,是根据32篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合KRT75 抗体。
KRT75 同义词: K6HF; KB18; PFB; keratin, type II cytoskeletal 75; CK-75; K75; cytokeratin type II; cytokeratin-75; hK6hf; keratin 75, type II; keratin-6 hair follicle; type II keratin-18; type II keratin-K6hf; type-II keratin Kb18
赛默飞世尔
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:150 (表 2). Hum Pathol (2017) ncbi |
小鼠 单克隆(AE3) |
| 赛默飞世尔 KRT75抗体(eBioscience, 14-900-80)被用于被用于流式细胞仪在人类样品上. F1000Res (2016) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo Scientific, AE1-AE3)被用于被用于免疫组化在人类样品上 (图 3d). Case Rep Pathol (2016) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo Scientific, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上 (图 5b). Breast Cancer Res Treat (2016) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(ThermoFisher Scientific, MA5-13156)被用于被用于免疫细胞化学在人类样品上浓度为1:50 (图 1). Future Oncol (2016) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(分子探针, 985542A)被用于被用于免疫组化-石蜡切片在人类样品上 (图 s3). Microbiome (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 3). Pathol Res Pract (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo Scientific, AE1/AE3)被用于被用于免疫组化在人类样品上 (表 2). Diagn Cytopathol (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(生活技术, MA5-13156)被用于被用于免疫细胞化学在fancy carp样品上. In Vitro Cell Dev Biol Anim (2015) ncbi |
小鼠 单克隆(AE1/AE3) | 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于. In Vitro Cell Dev Biol Anim (2015) ncbi | |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Lab.Vision, Ab-1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为10-20 ug/ml. Asian Pac J Cancer Prev (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo, MS-34)被用于被用于免疫组化-石蜡切片在小鼠样品上浓度为1:100 (图 s6). Nat Commun (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(ThermoFisher Scientific, AE1/AE3)被用于被用于免疫组化-石蜡切片在小鼠样品上浓度为1:200 (图 5). Development (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Neo Markers, MS343)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Comp Med (2014) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Hum Pathol (2014) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo Fisher Scientific, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Rom J Morphol Embryol (2014) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于被用于免疫细胞化学在人类样品上. Histopathology (2015) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo, AE1/AE3)被用于被用于免疫组化在人类样品上. BMC Med Imaging (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo Fisher, AE1/AE3)被用于被用于免疫细胞化学在人类样品上. Biomed Mater (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermoelectron, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上. BMC Med Imaging (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (表 2). Sci Rep (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化在人类样品上 (表 1). Head Face Med (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1-AE3)被用于被用于免疫组化在人类样品上浓度为1:200 (图 4). Surg Neurol Int (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化在人类样品上 (图 2). Diagn Pathol (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于被用于免疫细胞化学在大西洋鲑鱼样品上浓度为1:50 (图 2). Virol J (2013) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Med Sci Monit (2012) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Thermo Scientific, MS-343)被用于被用于免疫组化-石蜡切片在小鼠样品上. Anat Cell Biol (2011) ncbi |
小鼠 单克隆(AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:300 (表 2). J Comp Pathol (2009) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Cancer (2008) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Lab Vision, MS-343-P)被用于被用于免疫印迹在人类样品上 (图 5). Int J Cancer (2005) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:80 (表 1). Pathol Int (2004) ncbi |
小鼠 单克隆(AE1/AE3) |
| 赛默飞世尔 KRT75抗体(Zymed, AE1/AE3)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 2). Gynecol Oncol (2003) ncbi |
文章列表
- Wang X, Xia Q, Ni H, Ye S, Li R, Wang X, et al. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion. Hum Pathol. 2017;63:190-200 pubmed 出版商
- De Luca Johnson J, Zenali M. A Previously Undescribed Presentation of Mixed Adenoneuroendocrine Carcinoma. Case Rep Pathol. 2016;2016:9063634 pubmed
- Ahmed H, Abdul Gader Suliman R, Abd El Aziz M, Alshammari F. Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications. Asian Pac J Cancer Prev. 2015;16:653-6 pubmed
- Beck A, Brooks A, Zeiss C. Invasive ductular carcinoma in 2 rhesus macaques (Macaca mulatta). Comp Med. 2014;64:314-22 pubmed
- Costache M, Pătraşcu O, Dumitru A, Costache D, Voinea L, Simionescu O, et al. Histopathological findings concerning ocular melanomas. Rom J Morphol Embryol. 2014;55:649-53 pubmed
- Motomura K, Izumi T, Tateishi S, Sumino H, Noguchi A, Horinouchi T, et al. Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes. BMC Med Imaging. 2013;13:32 pubmed 出版商
- Lv S, Song Y, Xu J, Shu H, Zhou Z, An N, et al. A novel TP53 somatic mutation involved in the pathogenesis of pediatric choroid plexus carcinoma. Med Sci Monit. 2012;18:CS37-41 pubmed
- Lu S, Yu G, Zhu Y, Archer M. Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. Int J Cancer. 2005;116:847-52 pubmed
- Song S, Park S, Kim S, Suh Y. Oncocytic adrenocortical carcinomas: a pathological and immunohistochemical study of four cases in comparison with conventional adrenocortical carcinomas. Pathol Int. 2004;54:603-10 pubmed
- Kokenyesi R, Murray K, Benshushan A, Huntley E, Kao M. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol. 2003;89:60-72 pubmed